EMA Application withdrawn: Entolimod TMC (Entolimod) — TMC Pharma Services Ltd

View source ↗

Summary

The EMA withdrew the application for Entolimod (TMC) by TMC Pharma Services Ltd for Acute Radiation Syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Radiation Syndrome

Drugs mentioned

• Entolimod (entolimod)

Snippet

Status: Application withdrawn. Therapeutic area: Acute Radiation Syndrome. MAH: TMC Pharma Services Ltd. Decision date: 20/09/2018